BioCardia Inc. (NASDAQ: BCDA)
$3.17
-0.3700 ( -10.50% ) 87.0K
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
Market Data
Open
$3.17
Previous close
$3.54
Volume
87.0K
Market cap
$5.61M
Day range
$2.88 - $3.44
52 week range
$2.62 - $38.10
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
10-q | Quarterly Reports | 61 | May 14, 2024 |
8-k | 8K-related | 15 | May 01, 2024 |
4 | Insider transactions | 1 | Apr 19, 2024 |
def | Proxies and info statements | 5 | Apr 15, 2024 |
pre | Proxies and info statements | 5 | Apr 04, 2024 |
4 | Insider transactions | 1 | Mar 28, 2024 |
8-k | 8K-related | 15 | Mar 27, 2024 |
10-k | Annual reports | 85 | Mar 27, 2024 |
8-k | 8K-related | 16 | Mar 13, 2024 |
8-k | 8K-related | 16 | Mar 12, 2024 |